Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 31, 2011

Newron Pharmaceuticals Nabs Two Candidates from Merck Serono’s Pipeline

  • Newron Pharmaceuticals and Merck Serono have expanded their existing CNS therapeutics collaboration through an agreement that gives Newron a license to develop its partner’s clinical stage candidates pruvanserin and sarizotan. Under terms of the new deal, Merck retains a buy-back option for each compound on completion of proof-of-concept trials. Newron will have a co-development option if Merck decides to exercise its buy-back rights.

    The firms are already collaborating on the development of Newron’s Phase III-stage Parkinson disease drug safinamide. Under terms of this deal, signed in 2006, Merck Serono has exclusive rights to develop, manufacture, and commercialize safinamide for its lead indication of Parkinson disease, as well as Alzheimer disease and other therapeutic indications.  

    Provanserin and sarizotan are specific serotonin or dopamine receptor modulators for which existing clinical data supports further investigation and development, Newron claims. The firm will carry out additional preclinical work to assess their potential in CNS diseases before starting proof-of-concept studies.


Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »